LONDON--(BUSINESS WIRE)--Osmetech plc ('Osmetech' or the 'Company') (LSE:OMH), the fast developing international molecular diagnostics business announces that it has commenced clinical trials for its genetic eSensor® 2C9/VKOR test to be used as an aid in the identification of patients at risk for increased sensitivity for the widely used blood-thinning drug, warfarin.